Skip to main content
. 2022 Dec 16;7(78):eadd3899. doi: 10.1126/sciimmunol.add3899

Fig. 2. Ex vivo IFN-γ responses to SARS-CoV-2 BA.1 and BA.2 mutation pools.

Fig. 2.

(A) Overview of variant-defining mutations in the spike protein described for the different VOCs. (B to E) Variant mutation–specific T cell responses after complete vaccination (two doses of BNT162b2, mRNA-1273, and ChAdOx1 or one dose of Ad26.COV2.S; for heterologous (Heterol.) vaccine regimens, one dose of the vector vaccine ChAdOx1 followed by one dose of an mRNA vaccine) were assessed by IFN-γ ELISpot assays. (B) Percentage of individuals with BA.1 mutation pool–specific ex vivo IFN-γ T cell responses and (C) intensities of IFN-γ T cell responses in terms of calculated spot counts after mRNA, vector, or heterologous vaccination compared with COVID-19 convalescents (Conv.) and prepandemic (Pre.) donors. (D) Percentage of individuals with BA.2 mutation pool–specific ex vivo IFN-γ T cell responses and (E) intensities of IFN-γ T cell responses in terms of calculated spot counts. Responders are represented by colored symbols, and nonresponders are represented by clear symbols. Symbol shapes indicate the different vaccine products received by the donors. (C and E) Box plots represent the median with the 25th and 75th percentiles with minimum and maximum whiskers. (B and D) Fisher’s exact test was used. (C and E) Kruskal-Wallis test was used. If P values are not shown, then results were not significant.